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analyses, dominance was lost in ACEi-using and NYHA class II
patients; in these subgroups, the mean ICUR is €17,000–27,000/
QALY. CONCLUSIONS: Valsartan is expected to be cost/
effective for the treatment of Italian patients with mild-to-severe
CHF, and can result cost-saving in selected patients, as compared
to current standard care.
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OBJECTIVES: To determine the cost-effectiveness of endovascu-
lar aneurysm repair (EVAR) versus open surgical repair (OSR)
for acute (ruptured or symptomatic intact), infrarenal abdominal
aortic aneurysm (AAA) in an emergency setting. METHODS: A
two-stage cost-utility model was developed for the recent
appraisal of EVAR by the National Institute for Health and
Clinical Excellence in England and Wales to capture the lifetime
costs and beneﬁts of EVAR for non-ruptured AAA. This model
was adapted to capture the costs and health outcomes of EVAR
for acute AAA. The model population represented a 70-year-old,
ﬁt for open surgery, with an acute AAA. A decision-tree model
captured the short-term costs and health outcomes of patients
during the ﬁrst 30 days post repair, followed by a Markov model,
with monthly cycles during the ﬁrst 24 months and yearly cycles
thereafter, until death. Clinical endpoints included mortality,
complications and secondary interventions. Primary data sources
included a meta-analysis of 23 studies and the EVAR I ran-
domised controlled trial. Costs were applied from trial data and
national reference sources. A discount rate of 3.5% was applied
to costs and health outcomes. Univariate and multivariate sensi-
tivity analyses were performed for all parameters. An incremen-
tal cost-effectiveness ratio (ICER) reﬂecting incremental lifetime
costs per quality-adjusted life-year (QALY) gained was calculated
for the base-case analysis. RESULTS: EVAR dominates OSR in
the base case analysis. The average QALY gain at 30 years post
surgery was 0.064 for EVAR compared with OSR. The results
were not sensitive to changes in parameters. CONCLUSIONS:
The results suggest that EVAR for acute AAA is cost-effective
versus OSR with probabilities approaching 100% based on
willingness-to-pay thresholds of £20,000 and £30,000.
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OBJECTIVES: To evaluate the cost-effectiveness of Dabigatran
(DBG) compared to low-molecular-weight heparin (LMWH), for
the prevention of venous thromboembolism (VTE) following
total hip or knee replacement surgery (THR/TKR) from the
perspective of the UK NHS. METHODS: DBG (220 mg once
daily) was compared to LMWH in patients undergoing THR
(prophylaxis duration 28–35 days) and TKR (6–10 days). The
10-week post-surgery acute phase was modeled via a decision
tree. A Markov process (1 year cycle length) modelled long-term
events (recurrent VTE, post-thrombotic syndrome [PTS] and
consequences of intracranial haemorrhage) for patient’s remain-
ing lifetimes. Relative risks for VTE and bleed events were
derived from the DBG phase III studies, RE-NOVATE and
RE-MODEL which compared DBG with enoxaparin 40 mg once
daily. Probabilities of long-term events were estimated from pub-
lished longitudinal studies. Drug costs (for LMWH a weighted
average was used), resource use associated with administration
of prophylaxis and the management of clinical events, as well as
utility weights, were taken from national sources and published
literature. RESULTS: Thromboprophylaxis with DBG was less
costly than LMWH in TKR and substantially less in THR, since
no nursing time is required either in hospital or following dis-
charge for treatment administration. VTE and bleeding rates
were similar for DBG and LMWH (all differences non-
signiﬁcant). The probabilistic analysis estimated that DBG saved
£93 and £17 per patient on average in THR and TKR respec-
tively; the probability of cost-effectiveness was 99% in THR and
81% in TKR at a willingness to pay threshold of £20,000 per
QALY. Results were shown to be robust across a range of further
sensitivity analyses. CONCLUSIONS: DBG is cost-saving com-
pared to LMWH and non-inferior in terms of efﬁcacy and safety
to enoxaparin 40 mg once daily. Therefore DBG can conﬁdently
be regarded as cost-effective for the prevention of VTE in patients
undergoing THR or TKR.
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OBJECTIVES: An increasing number of studies is demonstrating
that postprandial blood glucose peaks (PPG), which are not
necessarily reﬂected by higher HbA1c values, represent a strong
risk factor for the development of cardiovascular complications.
This study aims to assess the economic effects of an improved
glycemic control by self-monitoring of blood glucose (SMBG)
with respect to coronary artery disease (CAD). METHODS: We
used a Markov model based on the UKPDS risk engine, compar-
ing two type 2 diabetic cohorts (100% male, age 57 years, BMI
29.0, systolic blood pressure 140 mmHg, total cholesterol
5.98 mmol/l, HDL 1.27 mmol/l, baseline HbA1c 8.0%), whereas
one cohort performed (SMBG) and the other not. In a ﬁrst
scenario, we assumed a HbA1c improvement of 0.6% in the
SMBG group compared to the control group. In a second
scenario, an additional reduction of PPG from 10 mmol/l to
7.8 mmol/l was assumed in the SMBG group. RESULTS: In
scenario 1 the mean life expectancy was 8.35 years (SMBG) vs.
8.33 years (No-SMBG), total cost was €15,793 (SMBG) and
€11,217 (No-SMBG). In scenario 2 the mean life expectancy was
8.19 years and 8.01 years (SMBG / No-SMBG group, respec-
tively). The cost effectiveness ratio (ICER) of using SMBG was
€228,800 per life year gained (LYG) in scenario 1 and €20,083/
LYG (scenario 2). CONCLUSIONS: Using only HbA1c as risk
factor for CAD leads to an underestimation of the potential
beneﬁts of SMBG compared to the combination of HbA1c and
PPG. This may lead to a restricted use or even to the exclusion of
a worthwhile health technology. The present assessment is
focused only on CAD and represents a conservative approach.
Further, it has to be examined whether PPG shows similar effects
in other diabetes related complications.
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